Esperion Therapeutics (ESPR) Asset Utilization Ratio (2019 - 2026)

Esperion Therapeutics' Asset Utilization Ratio history runs 8 years deep, the most recent figure standing at 0.9 for Q1 2026.

• Quarterly Asset Utilization Ratio rose 15.91% year-over-year to 0.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.9 (up 15.91% YoY) and the FY2025 annual result came in at 1.0, down 17.66% from the prior year.
• Asset Utilization Ratio was 0.9 for Q1 2026 at Esperion Therapeutics, down from 0.97 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 1.01 in Q4 2024 and bottomed at 0.21 in Q2 2022.
• A 5-year average of 0.61 and a median of 0.77 in 2024 frame the typical range for Asset Utilization Ratio.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio plunged 66.67% — and 2024, when it soared 144.97%.
• Esperion Therapeutics' Asset Utilization Ratio stood at 0.27 in 2022, then soared by 102.37% to 0.54 in 2023, then surged by 85.43% to 1.01 in 2024, then decreased by 3.83% to 0.97 in 2025, then dropped by 7.26% to 0.9 in 2026.
• Business Quant data shows ESPR's Asset Utilization Ratio at 0.9 in Q1 2026, 0.97 in Q4 2025, and 0.85 in Q3 2025.